EXEL vs IONS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
EXEL shows bullish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Key strengths include strong valuation and growth metrics.
IONS presents a significant disconnect between its market valuation and fundamental performance. While the Piotroski F-Score of 5/9 indicates stable financial health, the company is grappling with negative revenue growth (-10.30%) and a severe collapse in YoY EPS (-167.4%). Despite a massive 181% price surge over the last year, the valuation is extreme with a Price/Book of 25.10 and a Price/Sales of 13.16. Heavy insider selling by the CEO and CFO, combined with a bearish technical trend, suggests the current price is driven by speculative pipeline expectations rather than realized value.
Compare Another Pair
Related Comparisons
EXEL vs IONS: Head-to-Head Comparison
This page compares Exelixis, Inc. (EXEL) and Ionis Pharmaceuticals, Inc. (IONS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.